Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 56%
Buy 39%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc. is experiencing a positive financial trajectory largely driven by its commercial product, Brensocatib, which has shown strong sales growth, achieving approximately $144.6 million in revenue for Q4 2025, significantly exceeding expectations. The company benefits from a first-in-disease position with substantial peak sales potential estimated at around $9 billion for Brensocatib in the NCFB indication, reflecting robust market demand and a compelling clinical profile. Additionally, the sustained double-digit growth in Brensocatib sales over the years, combined with an improved outlook for cash flow positivity, suggests a strong foundation for future financial stability without the need for further capital raises.

Bears say

Insmed's stock faces a negative outlook primarily due to the disappointing results from the Brensocatib Phase 2b study in chronic rhinosinusitis without nasal polyps, which has diminished market expectations for future trials, including the CEDAR Phase 2 study in hidradenitis suppurativa. Furthermore, there are significant risks associated with multiple ongoing trials, including the potential for failure in the ENCORE Phase 3 and execution challenges related to the TPIP program, which may disrupt anticipated launches in international markets. Lastly, high quarterly cash burn rates, estimated at $165-170 million, coupled with uncertainties surrounding product approvals and clinical development timelines, may adversely affect the company's financial stability and growth prospects.

Insmed (INSM) has been analyzed by 18 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 39% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 18 analysts, Insmed (INSM) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $195.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $195.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.